These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 11812076)
1. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells. Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076 [TBL] [Abstract][Full Text] [Related]
2. p53 gene status and chemosensitivity in ovarian cancer. Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736 [TBL] [Abstract][Full Text] [Related]
3. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Song K; Cowan KH; Sinha BK Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075 [TBL] [Abstract][Full Text] [Related]
5. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Song K; Li Z; Seth P; Cowan KH; Sinha BK Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008 [TBL] [Abstract][Full Text] [Related]
6. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Mujoo K; Maneval DC; Anderson SC; Gutterman JU Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881 [TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876 [TBL] [Abstract][Full Text] [Related]
8. Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo. Ahn WS; Bae SM; Lee KH; Lee JM; Namkoong SE; Chun HJ; Kim CK; Kim YW Gynecol Oncol; 2004 Feb; 92(2):611-21. PubMed ID: 14766255 [TBL] [Abstract][Full Text] [Related]
9. [Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin]. Zhang Y; Lin C; Qian HL; Lang JH; Fu M; Zhang XY; Liang X; Duan H; Xiang Y Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):25-9. PubMed ID: 17575689 [TBL] [Abstract][Full Text] [Related]
10. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells. Akeshima R; Kigawa J; Takahashi M; Oishi T; Kanamori Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Terakawa N Br J Cancer; 2001 Jun; 84(11):1551-5. PubMed ID: 11384107 [TBL] [Abstract][Full Text] [Related]
11. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models. Nielsen LL Oncol Rep; 2000; 7(6):1191-6. PubMed ID: 11032912 [TBL] [Abstract][Full Text] [Related]
13. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938 [TBL] [Abstract][Full Text] [Related]
14. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Shono T; Tofilon PJ; Schaefer TS; Parikh D; Liu TJ; Lang FF Cancer Res; 2002 Feb; 62(4):1069-76. PubMed ID: 11861384 [TBL] [Abstract][Full Text] [Related]
15. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin. Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645 [TBL] [Abstract][Full Text] [Related]
16. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518 [TBL] [Abstract][Full Text] [Related]
18. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Heise C; Lemmon M; Kirn D Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251 [TBL] [Abstract][Full Text] [Related]
19. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma]. Song Y; Shen K; He CX Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518 [TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Wolf JK; Mills GB; Bazzet L; Bast RC; Roth JA; Gershenson DM Gynecol Oncol; 1999 Nov; 75(2):261-6. PubMed ID: 10525383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]